Literature DB >> 25431370

Meta-analysis study on the role of bone-derived neurotrophic factor Val66Met polymorphism in Parkinson's disease.

Stefania Mariani1, Mariacarla Ventriglia, Illaria Simonelli, Serena Bucossi, Mariacristina Siotto, Rosanna Squitti R.   

Abstract

To evaluate a possible involvement of the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in susceptibility to Parkinson's disease (PD), we performed a meta-analysis of all studies on the topic published from 2002 to 2014. This article reviews and compares the data from two previous meta-analyses, including two studies not previously considered. We selected studies referring to a genetic comparison between PD patients and healthy controls, so 15 studies involving 3754 cases and 4026 controls were included in our meta-analysis. We found no association between the Val66Met polymorphism and the risk of developing PD in our overall analysis. The ethnicity-specific meta-analysis produced no significant association either. Our data do not support a major role for the BDNF Val66Met polymorphism in the pathogenesis of PD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25431370     DOI: 10.1089/rej.2014.1612

Source DB:  PubMed          Journal:  Rejuvenation Res        ISSN: 1549-1684            Impact factor:   4.663


  4 in total

1.  Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.

Authors:  Małgorzata Michałowska; Małgorzata Chalimoniuk; Ewa Jówko; Iwona Przybylska; Józef Langfort; Beata Toczylowska; Anna Krygowska-Wajs; Urszula Fiszer
Journal:  Brain Behav       Date:  2020-02-05       Impact factor: 2.708

2.  The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats.

Authors:  Natosha M Mercado; Jennifer A Stancati; Caryl E Sortwell; Rebecca L Mueller; Samuel A Boezwinkle; Megan F Duffy; D Luke Fischer; Ivette M Sandoval; Fredric P Manfredsson; Timothy J Collier; Kathy Steece-Collier
Journal:  Neurobiol Dis       Date:  2020-11-11       Impact factor: 5.996

3.  Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer.

Authors:  Terence Ng; Shu Mei Teo; Hui Ling Yeo; Maung Shwe; Yan Xiang Gan; Yin Ting Cheung; Koon Mian Foo; Mooi Tai Cham; Jung Ah Lee; Yee Pin Tan; Gilbert Fan; Wei Sean Yong; Madhukumar Preetha; Wei-Jen Kiley Loh; Si-Lin Koo; Amit Jain; Guek Eng Lee; Mabel Wong; Rebecca Dent; Yoon Sim Yap; Raymond Ng; Chiea Chuen Khor; Han Kiat Ho; Alexandre Chan
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

Review 4.  Critical Issues in BDNF Val66Met Genetic Studies of Neuropsychiatric Disorders.

Authors:  Shih-Jen Tsai
Journal:  Front Mol Neurosci       Date:  2018-05-15       Impact factor: 5.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.